Charles River Adds ERS License to CRISPR/Cas9 Service Offering

WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL #LIFEatCRL–Charles River Laboratories International, Inc. (NYSE: CRL) today
announced the expansion of its CRISPR/Cas9 service offering with the
addition of a license from ERS
Genomics Limited
. The license, coupled with the existing license
through the Broad
Institute of MIT and Harvard
, allows Charles River to offer custom in
vivo
and in vitro genome editing.

“The addition of a license from ERS provides our clients with a robust
CRISPR/Cas9 gene-editing platform,” said Dr. Iva Morse, Corporate Vice
President, Chief Scientific Officer, Global Research Models and
Services. “Our offering allows clients to work with one company to
develop in vitro models and cell lines and later place them into in
vivo
studies. This end-to-end service increases the efficiency and
effectiveness of our clients’ research process.”

Charles River biologists employ CRISPR for target screening alone or
alongside RNAi screening with the Company’s shRNA library
(SilenceSelect®) to create complex, custom knock-in and knockout cell
lines with applications throughout the drug discovery continuum. In
addition, Charles River has existing partnerships globally for in vivo
model creation, including:

  • Mirimus,
    a leader in RNA interference technology specializing in the creation
    of customized genetically engineered mouse models. (North America
    only)
  • Laboratory
    Animal Resource Center, University of Tsukuba
    , one of Japan’s
    largest production institutes for genetically modified mice. (Japan
    only)
  • Phenomin
    ICS
    , a leader in mouse and rat creation and phenotyping. (Europe
    only)

To learn more about Charles River’s strategic CRISPR/Cas9 initiatives,
please visit the Company’s website.

About Charles River

Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.

Contacts

Charles River Laboratories International, Inc.
Investor Contact:
Susan
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media
Contact:

Amy Cianciaruso, 781-222-6168
Corporate Vice
President, Public Relations
amy.cianciaruso@crl.com